AdvisorShares Psychedelics ETFPSIL
Type
ETF
Peer group
Global equity
Net assets
$20.2M
Expense ratio
1.00%
1-year return
+60.7%
3 years, a year
+19.9%
5 years, a year
-22.0%
12-month yield
7.22%
Holdings
29
What it aims to do.
The AdvisorShares Psychedelics ETF (the Fund) seeks long-term capital appreciation.
Top 10 holdings.
| Holding | % of fund |
|---|---|
| RLMD Relmada Therapeutics Inc. | 10.17% |
| Ataibeckley Inc | 9.92% |
| DFTX Definium Therapeutics Inc | 8.52% |
| JOBY Drey Inst Pref Gov Mm-M | 7.89% |
| CMPS Compass Pathways plc | 6.74% |
| NBIX Neurocrine Biosciences Inc | 4.67% |
| JOBY Gh Research Plc | 4.66% |
| HELP Cybin Inc | 4.64% |
| JOBY Alkermes PLC | 4.61% |
| JNJ Johnson & Johnson | 4.56% |
More on PSIL.
- PSIL overview
- PSIL holdings
- PSIL risk
- PSIL costs
- PSIL money in and out
- PSIL share classes
- Compare PSIL with other funds
Returns after fees, from the fund's SEC filings up to Aug 2026. Past returns are not a promise. Not financial advice.